Representative examples include:

Learning impairments are associated with impaired dendrites of the hippocampus
Impaired motor development and functioning are associated with reduced size of the cerebellum
Hyperactivity is associated with decreased size of the corpus callosumFunctional difficulties may result from CNS damage in more than one domain, but common functional difficulties by domain include: Note that this is not an exhaustive list of difficulties. Achievement: Learning disabilities
Adaptive behavior: Poor impulse control, poor personal boundaries, poor anger management, stubbornness, intrusive behavior, too friendly with strangers, poor daily living skills, developmental delays
Attention: Attention-Deficit/Hyperactivity Disorder (ADHD), poor attention or concentration, distractible
Cognition: Intellectual disability, confusion under pressure, poor abstract skills, difficulty distinguishing between fantasy and reality, slower cognitive processing
Executive functioning: Poor judgment, Information-processing disorder, poor at perceiving patterns, poor cause and effect reasoning, inconsistent at linking words to actions, poor generalization ability
Language: Expressive or receptive language disorders, grasp parts but not whole concepts, lack understanding of metaphor, idioms, or sarcasm
Memory: Poor short-term memory, inconsistent memory and knowledge base
Motor skills: Poor handwriting, poor fine motor skills, poor gross motor skills, delayed motor skill development (e.g., riding a bicycle at appropriate age)
Sensory processing and soft neurological problems: sensory processing disorder, sensory defensiveness, undersensitivity to stimulation
Social communication: Intrude into conversations, inability to read nonverbal or social cues, "chatty" but without substance

Secondary disabilities
The secondary disabilities of FAS are those that arise later in life secondary to CNS damage.
These include: full blood count, protein electrophoresis, antibodies to the acetylcholine receptor (indicative of myasthenia), electrolytes, liver enzymes and renal function. Staging
The Masaoka Staging System is used widely and is based on the anatomic extent of disease at the time of surgery:
I:   Completely encapsulated
IIA: Microscopic invasion through the capsule into surrounding fatty tissue
IIB: Macroscopic invasion into capsule
III: Macroscopic invasion into adjacent organs
IVA: Pleural or pericardial implants
IVB: Lymphogenous or hematogenous metastasis to distant (extrathoracic) sites

Treatment
Surgery is the mainstay of treatment for thymoma. If the tumor is apparently invasive and large, preoperative (neoadjuvant) chemotherapy and/or radiotherapy may be used to decrease the size and improve resectability, before surgery is attempted. When the tumor is an early stage (Masaoka I through IIB), no further therapy is necessary. Removal of the thymus in adults does not appear to induce immune deficiency. In children, however, postoperative immunity may be abnormal and vaccinations for several infectious agents are recommended. Invasive thymomas may require additional treatment with radiotherapy and chemotherapy (cyclophosphamide, doxorubicin and cisplatin).. Recurrences of thymoma are described in 10-30% of cases up to 10 years after surgical resection, and in the majority of cases also pleural recurrences can be removed. Recently, surgical removal of pleural recurrences can be followed by hyperthermic intrathoracic perfusion chemotherapy or intrathoracic hyperthermic perfused chemotherapy (ITH). Prognosis
Prognosis is much worse for stage III or IV thymomas as compared with stage I and II tumors. Invasive thymomas uncommonly can also metastasize, generally to pleura, bones, liver or brain in approximately 7% of cases.